Last updated: February 20, 2026
Repaglinide, an oral antihyperglycemic agent used to control blood sugar levels in type 2 diabetes, is commercially produced by several pharmaceutical companies. These suppliers vary in geographic reach, manufacturing scale, and regulatory approvals.
Major Pharmaceutical Manufacturers
| Company |
Headquarters |
Manufacturing Locations |
Market Presence |
Notes |
| Novo Nordisk |
Denmark |
Denmark, US, others |
Global |
Patent expired in many regions; produces generics under licensing. |
| Mylan (now part of Viatris) |
US |
India, US |
Global |
Supplies generic repaglinide in multiple markets. |
| Sun Pharma |
India |
India, US, others |
Asia, US |
Produces generic formulations, approved in several countries. |
| Zydus Cadila |
India |
India |
India, select markets |
Offers affordable generic options. |
| Dr. Reddy’s Laboratories |
India |
India, US, others |
India, US |
Supplies repaglinide generics. |
Regulatory Approvals & Market Dynamics
- Patent Status: Repaglinide's patent expired in most regions by 2014, enabling multiple generic manufacturers to produce the drug.
- Generic Competition: Several Indian pharmaceutical firms hold FDA and EMA approvals, leading to increased market competition and lower prices.
- Supply Chain Challenges: Some suppliers face issues due to API shortages, impacting production volumes.
API Suppliers
Critical to repaglinide manufacturing are active pharmaceutical ingredient (API) producers:
- Chinese companies: Leading API suppliers for repaglinide; include Zhejiang Hisun Pharmaceutical and Jiangsu Hengrui Medicine.
- Indian API producers: Such as Aarti Industries and Mylan API units.
API manufacturing often occurs in China and India, with finished formulations assembled globally.
Market Share & Pricing
- Largest suppliers: Mylan and Sun Pharma dominate in lower-cost generic markets.
- Pricing trends: Generics have reduced wholesale prices by approximately 60% over the past five years.
- Supply risks: API shortages have caused temporary price hikes and stockouts in some regions.
Key Takeaways
- Repaglinide is produced by multiple generic manufacturers, mainly in India and China.
- Patent expiration has increased the number of suppliers, decreasing prices.
- API sourcing from China dominates, with Indian companies also significant players.
- Regulatory approvals enable global distribution, but supply chain disruptions affect availability.
- Large companies like Mylan and Sun Pharma lead in market share.
FAQs
1. Who are the leading global suppliers of repaglinide?
Mylan (Viatris), Sun Pharma, Zydus Cadila, and Dr. Reddy’s Laboratories, mostly based in India, are top producers.
2. Are there API shortages affecting repaglinide production?
Yes. API shortages from Chinese manufacturers have periodically impacted supply and prices.
3. Is repaglinide available as a generic?
Yes. Generic repaglinide is widely available following patent expiration.
4. Which countries are primary markets for repaglinide?
India, the US, and European countries represent significant markets for the drug.
5. How does API sourcing impact drug pricing?
Dependence on Chinese API producers can lead to supply risks, influencing availability and pricing globally.
References
[1] IMS Health. (2022). Global Prescription Market Data.
[2] European Medicines Agency. (2023). Marketing authorization approvals for repaglinide.
[3] U.S. Food and Drug Administration. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations.
[4] GlobalData. (2022). API Market Insights.
[5] IQVIA. (2022). Global Pharmaceutical Market Analysis.
